Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
aTyr PharmaATYR -4.98%14 3-1 Month Momentum % is -28.48% as of Jul. 27, 2026. GuruFocus rates ATYR with a GF Score™ of 14/100 and a GF Value™ of $0.45 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,393 Biotechnology companies, aTyr Pharma ranks worse than 78.68% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-27), aTyr Pharma's 3-1 Month Momentum % is -28.48%.
The industry rank for aTyr Pharma's 3-1 Month Momentum % or its related term are showing as below:
ATYR's 3-1 Month Momentum % is ranked worse than 78.68% of 1393
companies
in the Biotechnology industry
Industry Median: -10.79
vs ATYR: -28.48
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
aTyr Pharma 3-1 Month Momentum % Related Terms
ATYR vs IBO, BYSI, MCRB: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, aTyr Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
aTyr Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, aTyr Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where aTyr Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
aTyr Pharma (ATYR) has a 3-1 Month Momentum % of -28.48% as of Jul. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on aTyr Pharma and its competitors. According to the industry distribution chart, aTyr Pharma ranks #1096 out of 1393 companies in the Biotechnology industry, placing it in the top 78.7%.
Is aTyr Pharma's 3-1 Month Momentum % too high?
aTyr Pharma's current 3-1 Month Momentum % is -28.48%. Based on the distribution chart, aTyr Pharma ranks #1096 out of 1393 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, aTyr Pharma has a GF Score™ of 14/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does aTyr Pharma's 3-1 Month Momentum % compare to IBO and BYSI?
According to the Biotechnology industry distribution chart, aTyr Pharma ranks #1096 out of 1393 companies for 3-1 Month Momentum %. This places aTyr Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on aTyr Pharma and its competitors. aTyr Pharma's current 3-1 Month Momentum % is -28.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is aTyr Pharma stock overvalued right now?
Based on GuruFocus' analysis, aTyr Pharma (ATYR) is currently considered Fairly Valued. The stock's GF Value™ is $0.45, compared to a current price of $0.48 — trading 6.1% above its estimated fair value. The current 3-1 Month Momentum % is -28.48%. aTyr Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For aTyr Pharma (ATYR), the current 3-1 Month Momentum % is -28.48% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is aTyr Pharma (ATYR) Overvalued in 2026?
Based on GuruFocus' analysis, aTyr Pharma stock appears to be overvalued.
The current stock price of $0.48 is trading 6.1% above its estimated GF Value™ of $0.45.
GuruFocus considers aTyr Pharma to be Fairly Valued.
Key valuation signals for ATYR:
3-1 Month Momentum %: -28.48%
GF Value™: $0.45 vs. price of $0.48 (6.1% above fair value)
No single metric tells the full story. See the ATYR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
14GF Score
Get the complete analysis for ATYR
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATYR has been successfully added to your 
